Details

Autor(en) / Beteiligte

• Ge, Haitao
• Mu, Luyan
• Jin, Linchun
• Yang, Changlin
• Chang, Yifan Emily
• Long, Yu
• DeLeon, Gabriel
• Deleyrolle, Loic
• Mitchell, Duane A
• Kubilis, Paul S
• Lu, Dunyue
• Qi, Jiping
• Gu, Yunhe
• Lin, Zhiguo
• Huang, Jianping

Titel

Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM

Ist Teil von

• International journal of cancer, 2017-10, Vol.141 (7), p.1434-1444

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2017

Quelle

Access via Wiley Online Library

Beschreibungen/Notizen

• Tumor migration/metastasis and immunosuppression are major obstacles in effective cancer therapy. Incidentally, these 2 hurdles usually coexist inside tumors, therefore making therapy significantly more complicated, as both oncogenic mechanisms must be addressed for successful therapeutic intervention. Our recent report highlights that the tumor expression of a TNF family member, CD70, is correlated with poor survival for primary gliomas. In this study, we investigated how CD70 expression by GBM affects the characteristics of tumor cells and the tumor microenvironment. We found that the ablation of CD70 in primary GBM decreased CD44 and SOX2 gene expression, and inhibited tumor migration, growth and the ability to attract monocyte-derived M2 macrophages in vitro. In the tumor microenvironment, CD70 was associated with immune cell infiltrates, such as T cells; myeloid-derived suppressor cells; and monocytes/macrophages based on the RNA-sequencing profile. The CD163+ macrophages were far more abundant than T cells were. This overwhelming level of macrophages was identified only in GBM and not in low-grade gliomas and normal brain specimens, implying their tumor association. CD70 was detected only on tumor cells, not on macrophages, and was highly correlated with CD163 gene expression in primary GBM. Additionally, the co-expression of the CD70 and CD163 genes was found to correlate with decreased survival for patients with primary GBM. Together, these data suggest that CD70 expression is involved in promoting tumor aggressiveness and immunosuppression via tumor-associated macrophage recruitment/activation. Our current efforts to target this molecule using chimeric antigen receptor T cells hold great potential for treating patients with GBM.